drugset / Trial / NCT02265289

Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects

NCT02265289

Phase 1 Completed 14 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

To assess the influence of 75 mg Clopidogrel on the pharmacodynamics and safety of 30 mg Lefradafiban tid

Timeline

Start
1999-01
Primary completion
1999-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg
Subject Lefradafiban Small molecule 30 mg Oral

Indications

No indication recorded.